About Tetragenex

As you may or may not know Dr. John Feighner our former president recently passed away after a long battle with a blood disorder.  Dr. Feighner's uncompromising effort to help people led him to initially join Innapharma and we intend to fulfill his legacy by continuing our unwavering commitment to see nemifitide to commercialization. 

If you have any questions regarding the progress of our company or about the SB2 filing, please don’t hesitate to call, however, please understand that we are very limited in what we can discuss now that the company is in registration.

From Innapharma Inc. to Tetragenex Pharmaceuticals, Inc.

2003-2006

Due to a toxicology issue in a standard 3-month study, the FDA suspended the clinical program until additional preclinical studies were completed.  Due to this, the Company lost its ability to complete a public offering.  Having lost this ability, on April 15, 2003, the Company filed for protection under Chapter 11 of the bankruptcy code.   On November 26, 2004 as part of the reorganization agreement, Innapharma emerged from bankruptcy and merged into its wholly-owned subsidiary Tetragenex Pharmaceuticals.  The Company completed a  number of private placements, which provided the funding to get through bankruptcy and complete several preclinical trials that were required to get its clinical hold lifted.  These tests were performed and the FDA has since lifted our hold and allowed us to return to the clinic with nemifitide.